[go: up one dir, main page]

Bard et al., 2004 - Google Patents

High-risk papillomavirus infection is associated with altered antibody responses in genital tract: non-specific responses in HPV infection

Bard et al., 2004

Document ID
1113101876614745481
Author
Bard E
Riethmuller D
Meillet D
Pretet J
Schaal J
Mougin C
Seilles E
Publication year
Publication venue
Viral Immunology

External Links

Snippet

In order to gain more information about local humoral immune responses to HPV infection, we quantified IgG, IgM, secretory-IgA (S-IgA), and total-IgA by ELISA, and lysozyme and lactoferrin by TR-IFMA, in cervical and cervicovaginal secretions of 40 healthy women and …
Continue reading at www.liebertpub.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—AIDS or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/571—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus

Similar Documents

Publication Publication Date Title
Greer et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts
Nardelli-Haefliger et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus–like particles
Konya et al. Immunity to oncogenic human papillomaviruses
Caussy et al. Interaction of human immunodeficiency and papilloma viruses: association with anal epithelial abnormality in homosexual men
Mann et al. Occurrence of IgA and IgG antibodies to select peptides representing human papillomavirus type 16 among cervical cancer cases and controls
Emeny et al. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine
Tevi-Bénissan et al. In vivo semen-associated pH neutralization of cervicovaginal secretions
Kreiss et al. Human immunodeficiency virus, human papillomavirus, and cervical intraepithelial neoplasia in Nairobi prostitutes
Melbye et al. Immune status as a determinant of human papillomavirus detection and its association with anal epithelial abnormalities
Aurelian et al. Antibody to genital herpes simplex virus: association with cervical atypia and carcinoma in situ
Wideroff et al. Epidemiologic Determinants of Seroreactivity to Human Papillomavirus (HPV) Type 16 Virus-Like Particles in Cervical HPV-16 DNA—Positive and—Negative Women
Heim et al. Serum IgG, IgM, and IgA reactivity to human papillomavirus types 11 and 6 virus-like particles in different gynecologic patient groups
Slavinsky Iii et al. Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients
JP2011503208A (en) Efficient protein extraction from cells
Baillargeon et al. Epidemiology of human herpesvirus 6 (HHV-6) infection in pregnant and nonpregnant women
Dillner et al. Detection of IgA antibodies against human papillomavirus in cervical secretions from patients with cervical intraepithelial neoplasia
Wang et al. Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA
Cason et al. Detection of antibodies to a linear epitope on the major coat protein (L1) of human papillomavirus type‐16 (HPV‐16) in sera from patients with cervical intraepithelial neoplasia and children
Hagensee et al. Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men
Bard et al. High-risk papillomavirus infection is associated with altered antibody responses in genital tract: non-specific responses in HPV infection
Marais et al. Seroresponses to human papillomavirus types 16, 18, 31, 33, and 45 virus‐like particles in South African women with cervical cancer and cervical intraepithelial neoplasia
Dillner et al. Antibodies against papillomavirus antigens in cervical secretions from condyloma patients
Cameron et al. Human papillomavirus-specific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals
Cason et al. Transmission of cervical cancer-associated human papilloma viruses from mother to child
Wikström et al. Prospective study on the development of antibodies against human papillomavirus type 6 among patients with condyloma acuminata or new asymptomatic infection